REG - AstraZeneca PLC - ASTRAZENECA PRICES A $6 BILLION BOND ISSUE <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

11/11/2015 07:34

RNS Number : 2715F
AstraZeneca PLC
11 November 2015
AstraZeneca prices a $6 billion bond issue
AstraZeneca PLC announces that yesterday it conducted a global bond market transaction by issuing a total of $6bn of notes. The proceeds of the issue will be used to fund the previously announced acquisition of ZS Pharma, Inc., to repay certain outstanding commercial paper obligations, and for general corporate purposes. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of five tranches:
 $0.4bn of 3-year floating rate notes;
 $1.0bn of 3-year fixed rate notes with a coupon of 1.750%;
 $1.6bn of 5-year fixed rate notes with a coupon of 2.375%;
 $2.0bn of 10-year fixed rate notes with a coupon of 3.375%; and
 $1.0bn of 30-year fixed rate notes with a coupon of 4.375%.
The notes will be issued under AstraZeneca's existing automatic shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 26 November 2013. Such registration statement provides for the offer and sale from time to time of an indeterminate amount of AstraZeneca's debt securities and includes a prospectus that investors should read to obtain more complete information. The offering was made solely by means of a written prospectus forming part of the effective registration statement. 
A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Barclays Capital Inc. at +1 888 603 5847, HSBC Securities (USA) Inc at +1 866 811 8049, Merrill Lynch, Pierce, Fenner & Smith Incorporated at +1 800 294 1322 or Morgan Stanley & Co. LLC at +1 866 718 1649. You may also get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The bond issuance does not have any material impact to the Company's financial guidance for 2015.

11 November 2015
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information about AstraZeneca please visit: www.astrazeneca.com.
CONTACTS
Media Enquiries


Esra Erkal-Paler
UK/Global
+44 20 7604 8030
Vanessa Rhodes
UK/Global
+44 20 7604 8037
Ayesha Bharmal
UK/Global
+44 20 7604 8034
Karen Birmingham
UK/Global
+44 20 7604 8120
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Enquiries



UK



Thomas Kudsk Larsen
Oncology 
+44 20 7604 8199
+44 7818 524185
Eugenia Litz
RIA
+44 20 7604 8233
+44 7884 735627
Nick Stone
CVMD
+44 1763 263 994
+44 7717 618834
Craig Marks
Finance
+44 20 7604 8591
+44 7881 615764
Christer Gruvris
Consensus Forecasts
+44 20 7604 8126
+44 7827 836825
US



Lindsey Trickett
Oncology, ING
+1 301 398 5118
+1 240 543 7970
Mitch Chan
Oncology
+1 301 398 1849
+1 240 477 3771
Dial / Toll-Free

+1 301 398 3251
+1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, 
ING - Infection, Neuroscience and Gastrointestinal

This information is provided by RNS
The company news service from the London Stock Exchange
  END
IODKMMMMMGVGKZZ